Managing Side Effects
As with all medicines, you may feel side effects with Yurpeak®1
The most frequently reported adverse reactions in a clinical trial were gastrointestinal disorders, including nausea, diarrhea, constipation, and vomiting. In general, these reactions were mostly mild or moderate in severity and occurred more often during dose escalation and decreased over time.1
Tips for managing gastrointestinal symptoms
If you have nausea after taking Yurpeak®, talk to your doctor. In the meantime, these tips may help:
- Eat smaller, more frequent meals2
- At mealtimes, focus on recognizing when you feel full so you know when to stop eating. This may help you manage or prevent gastrointestinal symptoms3
- Avoid foods and beverages which might worsen symptoms, such as high-fat or fried foods, spicy foods, alcohol, or carbonated beverages, to help reduce symptoms like nausea and heartburn3
- Stay hydrated and gradually incorporate more fiber into your diet to help reduce constipation3
Dehydration2
- When starting your medicine, you may experience loss of fluids/ dehydration (due to vomiting and/or diarrhea), which may lead to decreased kidney function
- It is important to avoid dehydration by drinking plenty of fluids
Hypoglycaemia1,2
- Yurpeak® itself has a low risk of causing hypoglycemia, or low blood sugar
- If you are taking a type of drug called sulfonylurea or insulin, you have a higher chance of getting hypoglycemia
- Your doctor may decide to lower your dose of these medicines before adding Yurpeak® to your treatment
References
1. Yurpeak®(tirzepatide once weekly) India Prescribing Information | March
2025.
2. Gorgojo-Martinéz JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical
recommendations to manage gastrointestinal
adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary
expert consensus. J Clin Med.
2023;12:145. doi:10.3390/jcm12010145
3. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side
effects of GLP-1 receptor agonists in
obesity: recommendations for clinical practice. Postgrad Med. 2022;134:14-19.
doi:10.1080/ 00325481.2021.2002616
Learn about additional support options
MORE SUPPORT
Disclaimers:
This initiative is solely for patient support. It has been created with an intention to provide, assistance
and support to patients & NOT intended towards product promotion, NOR advertisement of any health care
professionals or doctors. Patients should be advised to consult and seek medical advice from their concerned
doctor/ health care professional before starting any treatment/medicine/ diet plan. Any advice regarding the
management of any medical condition is completely at the discretion of their consulting physician/doctor
(Registered Medical Practitioner). Cipla limited makes no representations as to the efficacy, accuracy,
appropriateness, or suitability of any specific tests, products, procedures, treatments, services, opinions,
healthcare providers or other information that may be shared through this screening/program/activity. Cipla
shall not be responsible for any direct, indirect, consequential or other damages arising therefrom. No personal
data is being collected, stored, or processed by Cipla as a part of this initiative.
Yurpeak®, KwikPen® and Lilly are registered trademark of Eli Lilly & Company, promoted and distributed by
Cipla in India.
The “CIPLA” mark and logo are the sole and intellectual property of Cipla Limited.
Nothing on this website should be construed as giving medical advice or making recommendations regarding any
health-related decision or action.
You should consult a doctor or other qualified healthcare professional regarding any questions about your
health or before making any treatment-related decisions.
The contents of this site are not intended to substitute the medical judgment of your treating
physicians.
This website is intended for people over 18 years of age.
This website is intended for the sole use of registered health care providers and patients prescribed with
Yurpeak® (tirzepatide) on their physician's advice.
Yurpeak® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company,
its subsidiaries, or affiliates. Yurpeak® is available by prescription only. To be sold by retail under
prescription of Endocrinologist or Internal Medicine specialists only.
For adverse events and safety reporting, please reach out to: drugsafety@cipla.com or report to Cipla Ltd. on
18002577779
For any additional information related to Lilly products, please reach out to:
queries_in-medinfo@lilly.com.